{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,20]],"date-time":"2026-10-20T19:39:08Z","timestamp":1792525148038,"version":"4.5.0"},"reference-count":102,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2026,7,1]],"date-time":"2026-07-01T00:00:00Z","timestamp":1782864000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,7,1]],"date-time":"2026-07-01T00:00:00Z","timestamp":1782864000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,7,1]],"date-time":"2026-07-01T00:00:00Z","timestamp":1782864000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2026,7,1]],"date-time":"2026-07-01T00:00:00Z","timestamp":1782864000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2026,7,1]],"date-time":"2026-07-01T00:00:00Z","timestamp":1782864000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2026,7,1]],"date-time":"2026-07-01T00:00:00Z","timestamp":1782864000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2026,7,1]],"date-time":"2026-07-01T00:00:00Z","timestamp":1782864000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Journal of Controlled Release"],"published-print":{"date-parts":[[2026,7]]},"DOI":"10.1016\/j.jconrel.2026.115019","type":"journal-article","created":{"date-parts":[[2026,5,14]],"date-time":"2026-05-14T15:18:13Z","timestamp":1778771893000},"page":"115019","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":9,"special_numbering":"C","title":["mRNA therapeutics: Molecular mechanisms, delivery platforms, regulatory frameworks, and equitable global access"],"prefix":"10.1016","volume":"395","author":[{"given":"Taruna","family":"Ikrar","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wachyudi","family":"Muchsin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alfi","family":"Sophian","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.jconrel.2026.115019_bb0005","doi-asserted-by":"crossref","first-page":"1465","DOI":"10.1126\/science.1690918","article-title":"Direct gene transfer into mouse muscle in vivo","volume":"247","author":"Wolff","year":"1990","journal-title":"Science"},{"key":"10.1016\/j.jconrel.2026.115019_bb0010","doi-asserted-by":"crossref","first-page":"732","DOI":"10.1038\/35099560","article-title":"Recognition of double-stranded RNA and activation of NF-\u03baB by Toll-like receptor 3","volume":"413","author":"Alexopoulou","year":"2001","journal-title":"Nature"},{"key":"10.1016\/j.jconrel.2026.115019_bb0015","doi-asserted-by":"crossref","first-page":"1526","DOI":"10.1126\/science.1093620","article-title":"Species-specific recognition of single-stranded RNA via toll-like receptor 7 and 8","volume":"303","author":"Heil","year":"2004","journal-title":"Science"},{"key":"10.1016\/j.jconrel.2026.115019_bb0020","doi-asserted-by":"crossref","first-page":"165","DOI":"10.1016\/j.immuni.2005.06.008","article-title":"Suppression of RNA recognition by toll-like receptors: the impact of nucleoside modification and the evolutionary origin of RNA","volume":"23","author":"Karik\u00f3","year":"2005","journal-title":"Immunity"},{"key":"10.1016\/j.jconrel.2026.115019_bb0025","doi-asserted-by":"crossref","first-page":"146","DOI":"10.1089\/nat.2018.0721","article-title":"Lipid nanoparticles enabling gene therapies: from concepts to clinical utility","volume":"28","author":"Kulkarni","year":"2018","journal-title":"Nucleic Acid Ther."},{"key":"10.1016\/j.jconrel.2026.115019_bb0030","doi-asserted-by":"crossref","first-page":"2603","DOI":"10.1056\/NEJMoa2034577","article-title":"Safety and efficacy of the BNT162b2 mRNA Covid-19 vaccine","volume":"383","author":"Polack","year":"2020","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.jconrel.2026.115019_bb0035","doi-asserted-by":"crossref","first-page":"403","DOI":"10.1056\/NEJMoa2035389","article-title":"Efficacy and safety of the mRNA-1273 SARS-CoV-2 vaccine","volume":"384","author":"Baden","year":"2021","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.jconrel.2026.115019_bb0040","doi-asserted-by":"crossref","first-page":"261","DOI":"10.1038\/nrd.2017.243","article-title":"mRNA vaccines \u2014 a new era in vaccinology","volume":"17","author":"Pardi","year":"2018","journal-title":"Nat. Rev. Drug Discov."},{"key":"10.1016\/j.jconrel.2026.115019_bb0045","doi-asserted-by":"crossref","first-page":"759","DOI":"10.1038\/nrd4278","article-title":"mRNA-based therapeutics \u2014 developing a new class of drugs","volume":"13","author":"Sahin","year":"2014","journal-title":"Nat. Rev. Drug Discov."},{"key":"10.1016\/j.jconrel.2026.115019_bb0050","doi-asserted-by":"crossref","first-page":"24075","DOI":"10.1073\/pnas.1908052116","article-title":"mRNA structure regulates protein expression through changes in functional half-life","volume":"116","author":"Mauger","year":"2019","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"10.1016\/j.jconrel.2026.115019_bb0055","doi-asserted-by":"crossref","first-page":"961","DOI":"10.1038\/gt.2010.52","article-title":"Phosphorothioate cap analogs increase stability and translational efficiency of RNA vaccines in immature dendritic cells","volume":"17","author":"Kuhn","year":"2010","journal-title":"Gene Ther."},{"key":"10.1016\/j.jconrel.2026.115019_bb0060","doi-asserted-by":"crossref","DOI":"10.1038\/s41467-022-28776-w","article-title":"Combinatorial optimization of mRNA structure, stability, and translation for RNA-based therapeutics","volume":"13","author":"Leppek","year":"2022","journal-title":"Nat. Commun."},{"key":"10.1016\/j.jconrel.2026.115019_bb0065","doi-asserted-by":"crossref","first-page":"1111","DOI":"10.1016\/j.cell.2015.02.029","article-title":"Codon optimality is a major determinant of mRNA stability","volume":"160","author":"Presnyak","year":"2015","journal-title":"Cell"},{"key":"10.1016\/j.jconrel.2026.115019_bb0070","doi-asserted-by":"crossref","first-page":"167","DOI":"10.1002\/wrna.1151","article-title":"Poly(A) binding proteins: are they all created equal?","volume":"4","author":"Goss","year":"2013","journal-title":"Wiley Interdiscip. Rev.: RNA"},{"key":"10.1016\/j.jconrel.2026.115019_bb0075","doi-asserted-by":"crossref","first-page":"1544","DOI":"10.1056\/NEJMoa2024671","article-title":"Evaluation of the mRNA-1273 vaccine against SARS-CoV-2 in nonhuman primates","volume":"383","author":"Corbett","year":"2020","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.jconrel.2026.115019_bb0080","doi-asserted-by":"crossref","first-page":"1187","DOI":"10.1016\/j.cell.2017.05.045","article-title":"Dynamic RNA modifications in gene expression regulation","volume":"169","author":"Roundtree","year":"2017","journal-title":"Cell"},{"key":"10.1016\/j.jconrel.2026.115019_bb0085","doi-asserted-by":"crossref","first-page":"1833","DOI":"10.1038\/mt.2008.200","article-title":"Incorporation of pseudouridine into mRNA yields superior nonimmunogenic vector with increased translational capacity and biological stability","volume":"16","author":"Karik\u00f3","year":"2008","journal-title":"Mol. Ther."},{"key":"10.1016\/j.jconrel.2026.115019_bb0090","doi-asserted-by":"crossref","DOI":"10.1093\/nar\/gkr695","article-title":"Generating the optimal mRNA for therapy: HPLC purification eliminates immune activation and improves translation of nucleoside-modified, protein-encoding mRNA","volume":"39","author":"Karik\u00f3","year":"2011","journal-title":"Nucleic Acids Res."},{"key":"10.1016\/j.jconrel.2026.115019_bb0095","doi-asserted-by":"crossref","first-page":"1174","DOI":"10.1016\/j.ymthe.2020.11.011","article-title":"Innate inhibiting proteins enhance expression and immunogenicity of self-amplifying RNA","volume":"29","author":"Blakney","year":"2021","journal-title":"Mol. Ther."},{"key":"10.1016\/j.jconrel.2026.115019_bb0100","doi-asserted-by":"crossref","first-page":"2629","DOI":"10.1038\/s41467-018-05096-6","article-title":"Engineering circular RNA for potent and stable translation in eukaryotic cells","volume":"9","author":"Wesselhoeft","year":"2018","journal-title":"Nat. Commun."},{"key":"10.1016\/j.jconrel.2026.115019_bb0105","doi-asserted-by":"crossref","first-page":"172","DOI":"10.1038\/nbt.1602","article-title":"Rational design of cationic lipids for siRNA delivery","volume":"28","author":"Semple","year":"2010","journal-title":"Nat. Biotechnol."},{"key":"10.1016\/j.jconrel.2026.115019_bb0110","doi-asserted-by":"crossref","first-page":"11","DOI":"10.1056\/NEJMoa1716153","article-title":"Patisiran, an RNAi therapeutic, for hereditary transthyretin amyloidosis","volume":"379","author":"Adams","year":"2018","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.jconrel.2026.115019_bb0115","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.omtn.2019.01.013","article-title":"Optimization of lipid nanoparticles for intramuscular administration of mRNA vaccines","volume":"15","author":"Hassett","year":"2019","journal-title":"Mol. Ther. Nucleic Acids"},{"key":"10.1016\/j.jconrel.2026.115019_bb0120","doi-asserted-by":"crossref","first-page":"638","DOI":"10.1038\/nbt.2612","article-title":"Image-based analysis of lipid nanoparticle-mediated siRNA delivery, intracellular trafficking and endosomal escape","volume":"31","author":"Gilleron","year":"2013","journal-title":"Nat. Biotechnol."},{"key":"10.1016\/j.jconrel.2026.115019_bb0125","doi-asserted-by":"crossref","first-page":"60","DOI":"10.1186\/s13073-017-0450-0","article-title":"Advances in the delivery of RNA therapeutics: from concept to clinical reality","volume":"9","author":"Kaczmarek","year":"2017","journal-title":"Genome Med."},{"key":"10.1016\/j.jconrel.2026.115019_bb0130","doi-asserted-by":"crossref","first-page":"987","DOI":"10.3390\/pharmaceutics13070987","article-title":"Cell-penetrating peptides and transportans","volume":"13","author":"Langel","year":"2021","journal-title":"Pharmaceutics"},{"key":"10.1016\/j.jconrel.2026.115019_bb0135","doi-asserted-by":"crossref","first-page":"9","DOI":"10.1038\/s41551-019-0507-z","article-title":"Functional extracellular vesicles aplenty","volume":"4","author":"Zickler","year":"2020","journal-title":"Nat. Biomed. Eng."},{"key":"10.1016\/j.jconrel.2026.115019_bb0140","doi-asserted-by":"crossref","first-page":"1532","DOI":"10.1056\/NEJMoa2119451","article-title":"Covid-19 vaccine effectiveness against the Omicron (B.1.1.529) variant","volume":"386","author":"Andrews","year":"2022","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.jconrel.2026.115019_bb0145","series-title":"A Phase 3 Randomized Study to Evaluate the Efficacy, Safety and Immunogenicity of mRNA-1010 Seasonal Influenza Vaccine","author":"Moderna Inc.","year":"2022"},{"key":"10.1016\/j.jconrel.2026.115019_bb0150","first-page":"23","article-title":"Safety and immunogenicity of a single dose of mRNA RSV vaccine in older adults","volume":"229","author":"Meng","year":"2024","journal-title":"J. Infect. Dis."},{"key":"10.1016\/j.jconrel.2026.115019_bb0155","doi-asserted-by":"crossref","first-page":"1279","DOI":"10.1056\/NEJMoa2208343","article-title":"A bivalent omicron-containing booster vaccine against Covid-19","volume":"387","author":"Chalkias","year":"2022","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.jconrel.2026.115019_bb0160","doi-asserted-by":"crossref","DOI":"10.1016\/j.nantod.2019.100766","article-title":"Three decades of messenger RNA vaccine development","volume":"28","author":"Verbeke","year":"2019","journal-title":"Nano Today"},{"key":"10.1016\/j.jconrel.2026.115019_bb0165","doi-asserted-by":"crossref","first-page":"1355","DOI":"10.1126\/science.aar7112","article-title":"Personalized vaccines for cancer immunotherapy","volume":"359","author":"Sahin","year":"2018","journal-title":"Science"},{"key":"10.1016\/j.jconrel.2026.115019_bb0170","doi-asserted-by":"crossref","first-page":"144","DOI":"10.1038\/s41586-023-06063-y","article-title":"Personalized RNA neoantigen vaccines stimulate T cells in pancreatic cancer","volume":"618","author":"Rojas","year":"2023","journal-title":"Nature"},{"key":"10.1016\/j.jconrel.2026.115019_bb0175","doi-asserted-by":"crossref","first-page":"632","DOI":"10.1016\/S0140-6736(23)02268-7","article-title":"Individualised neoantigen therapy mRNA-4157 (V940) plus pembrolizumab versus pembrolizumab monotherapy in resected melanoma (KEYNOTE-942): a randomised, phase 2b study","volume":"403","author":"Weber","year":"2024","journal-title":"Lancet"},{"key":"10.1016\/j.jconrel.2026.115019_bb0180","doi-asserted-by":"crossref","first-page":"41","DOI":"10.1186\/s12943-021-01335-5","article-title":"mRNA vaccine for cancer immunotherapy","volume":"20","author":"Miao","year":"2021","journal-title":"Mol. Cancer"},{"key":"10.1016\/j.jconrel.2026.115019_bb0185","doi-asserted-by":"crossref","first-page":"549","DOI":"10.1039\/D1BM01454D","article-title":"Optimization of phospholipid chemistry for improved lipid nanoparticle (LNP) delivery of messenger RNA (mRNA)","volume":"10","author":"Alvarez-Benedicto","year":"2022","journal-title":"Biomater. Sci."},{"key":"10.1016\/j.jconrel.2026.115019_bb0190","doi-asserted-by":"crossref","first-page":"519","DOI":"10.1016\/j.ebiom.2019.07.003","article-title":"Long-term efficacy and safety of mRNA therapy in two murine models of methylmalonic acidemia","volume":"45","author":"An","year":"2019","journal-title":"EBioMedicine"},{"key":"10.1016\/j.jconrel.2026.115019_bb0195","doi-asserted-by":"crossref","first-page":"1899","DOI":"10.1038\/s41591-018-0199-z","article-title":"Systemic messenger RNA as an etiological treatment for acute intermittent porphyria","volume":"24","author":"Jiang","year":"2018","journal-title":"Nat. Med."},{"key":"10.1016\/j.jconrel.2026.115019_bb0200","doi-asserted-by":"crossref","first-page":"1059","DOI":"10.1038\/s41551-021-00786-x","article-title":"Optimization of lipid nanoparticles for the delivery of nebulized therapeutic mRNA to the lungs","volume":"5","author":"Lokugamage","year":"2021","journal-title":"Nat. Biomed. Eng."},{"key":"10.1016\/j.jconrel.2026.115019_bb0205","doi-asserted-by":"crossref","first-page":"2227","DOI":"10.1016\/j.celrep.2018.02.014","article-title":"A single administration of CRISPR\/Cas9 lipid nanoparticles achieves robust and persistent in vivo genome editing","volume":"22","author":"Finn","year":"2018","journal-title":"Cell Rep."},{"key":"10.1016\/j.jconrel.2026.115019_bb0210","doi-asserted-by":"crossref","first-page":"493","DOI":"10.1056\/NEJMoa2107454","article-title":"CRISPR-Cas9 in vivo gene editing for transthyretin amyloidosis","volume":"385","author":"Gillmore","year":"2021","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.jconrel.2026.115019_bb0215","doi-asserted-by":"crossref","first-page":"824","DOI":"10.1038\/s41587-020-0561-9","article-title":"Genome editing with CRISPR-Cas nucleases, base editors, transposons and prime editors","volume":"38","author":"Anzalone","year":"2020","journal-title":"Nat. Biotechnol."},{"key":"10.1016\/j.jconrel.2026.115019_bb0220","doi-asserted-by":"crossref","first-page":"997","DOI":"10.1016\/j.xphs.2020.12.006","article-title":"Addressing the cold reality of mRNA vaccine stability","volume":"110","author":"Crommelin","year":"2021","journal-title":"J. Pharm. Sci."},{"key":"10.1016\/j.jconrel.2026.115019_bb0225","doi-asserted-by":"crossref","first-page":"305","DOI":"10.2147\/IJN.S123062","article-title":"Achieving long-term stability of lipid nanoparticles: examining the effect of pH, temperature, and lyophilization","volume":"12","author":"Ball","year":"2017","journal-title":"Int. J. Nanomedicine"},{"key":"10.1016\/j.jconrel.2026.115019_bb0230","doi-asserted-by":"crossref","first-page":"1078","DOI":"10.1038\/s41578-021-00358-0","article-title":"Lipid nanoparticles for mRNA delivery","volume":"6","author":"Hou","year":"2021","journal-title":"Nat. Rev. Mater."},{"key":"10.1016\/j.jconrel.2026.115019_bb0235","doi-asserted-by":"crossref","first-page":"313","DOI":"10.1038\/s41565-020-0669-6","article-title":"Selective organ targeting (SORT) nanoparticles for tissue-specific mRNA delivery and CRISPR-Cas gene editing","volume":"15","author":"Cheng","year":"2020","journal-title":"Nat. Nanotechnol."},{"key":"10.1016\/j.jconrel.2026.115019_bb0240","doi-asserted-by":"crossref","DOI":"10.1016\/j.isci.2021.103479","article-title":"The mRNA-LNP platform's lipid nanoparticle component used in preclinical vaccine studies is highly inflammatory","volume":"24","author":"Ndeupen","year":"2021","journal-title":"iScience"},{"key":"10.1016\/j.jconrel.2026.115019_bb0245","doi-asserted-by":"crossref","first-page":"471","DOI":"10.1161\/CIRCULATIONAHA.121.056135","article-title":"Myocarditis with COVID-19 mRNA vaccines","volume":"144","author":"Bozkurt","year":"2021","journal-title":"Circulation"},{"key":"10.1016\/j.jconrel.2026.115019_bb0250","doi-asserted-by":"crossref","first-page":"1617","DOI":"10.1111\/all.14711","article-title":"Allergic reactions to the first COVID-19 vaccine: a potential role of polyethylene glycol?","volume":"76","author":"Cabanillas","year":"2021","journal-title":"Allergy"},{"key":"10.1016\/j.jconrel.2026.115019_bb0255","doi-asserted-by":"crossref","first-page":"1712","DOI":"10.1016\/j.jaci.2016.04.058","article-title":"Pre-existing anti-PEG antibodies are associated with severe immediate allergic reactions to pegnivacogin","volume":"138","author":"Povsic","year":"2016","journal-title":"J. Allergy Clin. Immunol."},{"key":"10.1016\/j.jconrel.2026.115019_bb0260","doi-asserted-by":"crossref","DOI":"10.1002\/biot.201800376","article-title":"Emerging technologies for low-cost, rapid vaccine manufacture","volume":"14","author":"Kis","year":"2019","journal-title":"Biotechnol. J."},{"key":"10.1016\/j.jconrel.2026.115019_bb0265","doi-asserted-by":"crossref","first-page":"10604","DOI":"10.1093\/nar\/gkab764","article-title":"Theoretical basis for stabilizing messenger RNA through secondary structure design","volume":"49","author":"Wayment-Steele","year":"2021","journal-title":"Nucleic Acids Res."},{"key":"10.1016\/j.jconrel.2026.115019_bb0270","doi-asserted-by":"crossref","first-page":"17095","DOI":"10.1021\/jacs.8b08976","article-title":"Nanoparticles that deliver RNA to bone marrow identified by in vivo directed evolution","volume":"140","author":"Sago","year":"2018","journal-title":"J. Am. Chem. Soc."},{"key":"10.1016\/j.jconrel.2026.115019_bb0275","doi-asserted-by":"crossref","first-page":"395","DOI":"10.1146\/annurev-med-042617-101816","article-title":"Harnessing tumor mutations for truly individualized cancer vaccines","volume":"70","author":"Vormehr","year":"2019","journal-title":"Annu. Rev. Med."},{"key":"10.1016\/j.jconrel.2026.115019_bb0280","article-title":"Ultrasound-mediated blood-brain barrier opening for drug and gene delivery","volume":"16","author":"Bhattarai","year":"2022","journal-title":"Front. Neurosci."},{"key":"10.1016\/j.jconrel.2026.115019_bb0285","series-title":"Regulatory Considerations for mRNA Vaccines: A Framework for Health Authorities","author":"World Health Organization","year":"2022"},{"key":"10.1016\/j.jconrel.2026.115019_bb0290","doi-asserted-by":"crossref","first-page":"383","DOI":"10.1038\/s41577-019-0143-6","article-title":"The human antibody response to influenza a virus infection and vaccination","volume":"19","author":"Krammer","year":"2019","journal-title":"Nat. Rev. Immunol."},{"key":"10.1016\/j.jconrel.2026.115019_bb0295","doi-asserted-by":"crossref","first-page":"43","DOI":"10.1007\/978-1-62703-260-5_3","article-title":"HPLC purification of in vitro transcribed long RNA","volume":"969","author":"Weissman","year":"2013","journal-title":"Methods Mol. Biol."},{"key":"10.1016\/j.jconrel.2026.115019_bb0300","doi-asserted-by":"crossref","first-page":"1586","DOI":"10.1038\/s41587-022-01491-z","article-title":"Unlocking the promise of mRNA therapeutics","volume":"40","author":"Rohner","year":"2022","journal-title":"Nat. Biotechnol."},{"key":"10.1016\/j.jconrel.2026.115019_bb0305","doi-asserted-by":"crossref","first-page":"318","DOI":"10.1038\/d41586-021-02483-w","article-title":"The tangled history of mRNA vaccines","volume":"597","author":"Dolgin","year":"2021","journal-title":"Nature"},{"key":"10.1016\/j.jconrel.2026.115019_bb0310","doi-asserted-by":"crossref","first-page":"11","DOI":"10.1038\/s41541-020-0159-8","article-title":"The promise of mRNA vaccines: a biotech and industrial perspective","volume":"5","author":"Jackson","year":"2020","journal-title":"NPJ Vaccines"},{"key":"10.1016\/j.jconrel.2026.115019_bb0315","doi-asserted-by":"crossref","first-page":"710","DOI":"10.1016\/j.ymthe.2019.02.012","article-title":"Delivering the messenger: advances in technologies for therapeutic mRNA delivery","volume":"27","author":"Kowalski","year":"2019","journal-title":"Mol. Ther."},{"key":"10.1016\/j.jconrel.2026.115019_bb0320","first-page":"523","article-title":"Naturally occurring nucleoside modifications suppress the immunostimulatory activity of RNA","volume":"10","author":"Karik\u00f3","year":"2007","journal-title":"Curr. Opin. Drug Discov. Devel."},{"key":"10.1016\/j.jconrel.2026.115019_bb0325","doi-asserted-by":"crossref","first-page":"14","DOI":"10.1016\/j.coi.2020.01.008","article-title":"Recent advances in mRNA vaccine technology","volume":"65","author":"Pardi","year":"2020","journal-title":"Curr. Opin. Immunol."},{"key":"10.1016\/j.jconrel.2026.115019_bb0330","doi-asserted-by":"crossref","first-page":"329","DOI":"10.1016\/j.copbio.2021.09.016","article-title":"Principles for designing an optimal mRNA lipid nanoparticle vaccine","volume":"73","author":"Kon","year":"2022","journal-title":"Curr. Opin. Biotechnol."},{"key":"10.1016\/j.jconrel.2026.115019_bb0335","doi-asserted-by":"crossref","first-page":"16982","DOI":"10.1021\/acsnano.1c04996","article-title":"Lipid nanoparticles \u2014 from liposomes to mRNA vaccine delivery, a landscape of research diversity and advancement","volume":"15","author":"Tenchov","year":"2021","journal-title":"ACS Nano"},{"key":"10.1016\/j.jconrel.2026.115019_bb0340","doi-asserted-by":"crossref","DOI":"10.1016\/j.ijpharm.2021.120586","article-title":"mRNA-lipid nanoparticle COVID-19 vaccines: structure and stability","volume":"601","author":"Schoenmaker","year":"2021","journal-title":"Int. J. Pharm."},{"key":"10.1016\/j.jconrel.2026.115019_bb0345","doi-asserted-by":"crossref","first-page":"94","DOI":"10.1038\/s41392-022-00950-y","article-title":"Advances in COVID-19 mRNA vaccine development","volume":"7","author":"Fang","year":"2022","journal-title":"Signal Transduct. Target. Ther."},{"key":"10.1016\/j.jconrel.2026.115019_bb0350","doi-asserted-by":"crossref","first-page":"840","DOI":"10.1038\/s41587-022-01294-2","article-title":"The clinical progress of mRNA vaccines and immunotherapies","volume":"40","author":"Barbier","year":"2022","journal-title":"Nat. Biotechnol."},{"key":"10.1016\/j.jconrel.2026.115019_bb0355","doi-asserted-by":"crossref","DOI":"10.3389\/fbioe.2021.628137","article-title":"The limitless future of RNA therapeutics","volume":"9","author":"Damase","year":"2021","journal-title":"Front. Bioeng. Biotechnol."},{"key":"10.1016\/j.jconrel.2026.115019_bb0360","doi-asserted-by":"crossref","first-page":"222","DOI":"10.1038\/nature23003","article-title":"Personalized RNA mutanome vaccines mobilize poly-specific therapeutic immunity against cancer","volume":"547","author":"Sahin","year":"2017","journal-title":"Nature"},{"key":"10.1016\/j.jconrel.2026.115019_bb0365","doi-asserted-by":"crossref","first-page":"5976","DOI":"10.1172\/JCI134915","article-title":"mRNA vaccine-induced neoantigen-specific T cell immunity in patients with gastrointestinal cancer","volume":"130","author":"Cafri","year":"2020","journal-title":"J. Clin. Invest."},{"key":"10.1016\/j.jconrel.2026.115019_bb0370","doi-asserted-by":"crossref","first-page":"1281","DOI":"10.1016\/j.immuni.2020.11.009","article-title":"SARS-CoV-2 mRNA vaccines foster potent antigen-specific germinal center responses","volume":"53","author":"Lederer","year":"2020","journal-title":"Immunity"},{"key":"10.1016\/j.jconrel.2026.115019_bb0375","doi-asserted-by":"crossref","first-page":"319","DOI":"10.4155\/tde-2016-0006","article-title":"mRNA vaccine delivery using lipid nanoparticles","volume":"7","author":"Reichmuth","year":"2016","journal-title":"Ther. Deliv."},{"key":"10.1016\/j.jconrel.2026.115019_bb0380","doi-asserted-by":"crossref","DOI":"10.1016\/j.biotechadv.2020.107534","article-title":"The challenge and prospect of mRNA therapeutics landscape","volume":"40","author":"Weng","year":"2020","journal-title":"Biotechnol. Adv."},{"key":"10.1016\/j.jconrel.2026.115019_bb0385","doi-asserted-by":"crossref","first-page":"265","DOI":"10.1038\/s41576-021-00439-4","article-title":"Drug delivery systems for RNA therapeutics","volume":"23","author":"Paunovska","year":"2022","journal-title":"Nat. Rev. Genet."},{"key":"10.1016\/j.jconrel.2026.115019_bb0390","doi-asserted-by":"crossref","first-page":"2424","DOI":"10.1038\/s41467-020-16248-y","article-title":"Synergistic lipid compositions for albumin receptor mediated delivery of mRNA to the liver","volume":"11","author":"Miao","year":"2020","journal-title":"Nat. Commun."},{"key":"10.1016\/j.jconrel.2026.115019_bb0395","doi-asserted-by":"crossref","first-page":"20083","DOI":"10.1002\/anie.202008082","article-title":"Imidazole-based synthetic lipidoids for in vivo mRNA delivery into primary T lymphocytes","volume":"59","author":"Zhao","year":"2020","journal-title":"Angew. Chem. Int. Ed."},{"key":"10.1016\/j.jconrel.2026.115019_bb0400","doi-asserted-by":"crossref","DOI":"10.1073\/pnas.2109256118","article-title":"On the mechanism of tissue-specific mRNA delivery by selective organ targeting nanoparticles","volume":"118","author":"Dilliard","year":"2021","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"10.1016\/j.jconrel.2026.115019_bb0405","doi-asserted-by":"crossref","first-page":"463","DOI":"10.1007\/s12195-020-00619-y","article-title":"Naturally derived membrane lipids impact nanoparticle-based messenger RNA delivery","volume":"13","author":"Kim","year":"2020","journal-title":"Cell. Mol. Bioeng."},{"key":"10.1016\/j.jconrel.2026.115019_bb0410","doi-asserted-by":"crossref","first-page":"1509","DOI":"10.1016\/j.ymthe.2018.03.010","article-title":"A novel amino lipid series for mRNA delivery: improved endosomal escape and sustained expression","volume":"26","author":"Sabnis","year":"2018","journal-title":"Mol. Ther."},{"key":"10.1016\/j.jconrel.2026.115019_bb0415","first-page":"71","article-title":"Formulation and delivery technologies for mRNA vaccines","volume":"440","author":"Zeng","year":"2022","journal-title":"Curr. Top. Microbiol. Immunol."},{"key":"10.1016\/j.jconrel.2026.115019_bb0420","doi-asserted-by":"crossref","first-page":"14604","DOI":"10.1073\/pnas.1209367109","article-title":"Nonviral delivery of self-amplifying RNA vaccines","volume":"109","author":"Geall","year":"2012","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"10.1016\/j.jconrel.2026.115019_bb0425","doi-asserted-by":"crossref","first-page":"446","DOI":"10.1016\/j.ymthe.2017.11.017","article-title":"Self-amplifying RNA vaccines give equivalent protection against influenza to mRNA vaccines but at much lower doses","volume":"26","author":"Vogel","year":"2018","journal-title":"Mol. Ther."},{"key":"10.1016\/j.jconrel.2026.115019_bb0430","doi-asserted-by":"crossref","first-page":"102","DOI":"10.3390\/pharmaceutics12020102","article-title":"Opportunities and challenges in the delivery of mRNA-based vaccines","volume":"12","author":"Wadhwa","year":"2020","journal-title":"Pharmaceutics"},{"key":"10.1016\/j.jconrel.2026.115019_bb0435","doi-asserted-by":"crossref","first-page":"54","DOI":"10.1186\/s12967-019-1804-8","article-title":"How mRNA therapeutics are entering the monogenic disease field","volume":"17","author":"Van Hoecke","year":"2019","journal-title":"J. Transl. Med."},{"key":"10.1016\/j.jconrel.2026.115019_bb0440","series-title":"Guideline on the Quality, Non-clinical and Clinical Aspects of Gene Therapy Medicinal Products. EMA\/CAT\/80183\/2014","author":"European Medicines Agency","year":"2018"},{"key":"10.1016\/j.jconrel.2026.115019_bb0445","series-title":"Guidance for Industry: mRNA Drug Products and Related Substances","author":"US Food and Drug Administration","year":"2023"},{"key":"10.1016\/j.jconrel.2026.115019_bb0450","doi-asserted-by":"crossref","first-page":"305","DOI":"10.1038\/d41573-020-00151-8","article-title":"The COVID-19 vaccine development landscape","volume":"19","author":"Le","year":"2020","journal-title":"Nat. Rev. Drug Discov."},{"key":"10.1016\/j.jconrel.2026.115019_bb0455","doi-asserted-by":"crossref","first-page":"589","DOI":"10.1038\/s41586-020-2639-4","article-title":"Phase I\/II study of COVID-19 RNA vaccine BNT162b1 in adults","volume":"586","author":"Mulligan","year":"2020","journal-title":"Nature"},{"key":"10.1016\/j.jconrel.2026.115019_bb0460","first-page":"e777","article-title":"Equity in access to mRNA vaccines in sub-Saharan Africa","volume":"10","author":"Bah","year":"2022","journal-title":"Lancet Glob. Health"},{"key":"10.1016\/j.jconrel.2026.115019_bb0465","article-title":"Regulatory framework for mRNA vaccines in the Asia-Pacific region","volume":"23","author":"Venkatesan","year":"2023","journal-title":"Lancet Infect. Dis."},{"key":"10.1016\/j.jconrel.2026.115019_bb0470","series-title":"Pedoman registrasi vaksin mRNA di Indonesia","author":"Badan Pengawas Obat dan Makanan (BPOM)","year":"2022"},{"key":"10.1016\/j.jconrel.2026.115019_bb0475","series-title":"Guidance for Organizations Performing In Vitro Diagnostic Device Studies","author":"World Health Organization","year":"2020"},{"key":"10.1016\/j.jconrel.2026.115019_bb0480","doi-asserted-by":"crossref","first-page":"850","DOI":"10.1038\/s41551-018-0284-0","article-title":"Restoration of tumour-growth suppression in vivo via systemic nanoparticle-mediated delivery of PTEN mRNA","volume":"2","author":"Islam","year":"2018","journal-title":"Nat. Biomed. Eng."},{"key":"10.1016\/j.jconrel.2026.115019_bb0485","doi-asserted-by":"crossref","DOI":"10.1155\/2015\/794528","article-title":"RNA-based vaccines in cancer immunotherapy","volume":"2015","author":"McNamara","year":"2015","journal-title":"J. Immunol. Res."},{"key":"10.1016\/j.jconrel.2026.115019_bb0490","doi-asserted-by":"crossref","DOI":"10.3390\/ijms21186582","article-title":"mRNA vaccine era \u2014 mechanisms, drug platform and clinical prospection","volume":"21","author":"Xu","year":"2020","journal-title":"Int. J. Mol. Sci."},{"key":"10.1016\/j.jconrel.2026.115019_bb0495","doi-asserted-by":"crossref","first-page":"490","DOI":"10.1016\/j.mattod.2026.01.004","article-title":"Phospholipids tailor mRNA lipid nanoparticle delivery efficacy and immunogenicity","volume":"92","author":"Shi","year":"2026","journal-title":"Mater. Today"},{"key":"10.1016\/j.jconrel.2026.115019_bb0500","doi-asserted-by":"crossref","DOI":"10.1016\/j.mattod.2025.12.034","article-title":"A material toolbox for engineering targeted lipid nanoparticles for RNA therapies","volume":"93","author":"Yoo","year":"2026","journal-title":"Mater. Today"},{"key":"10.1016\/j.jconrel.2026.115019_bb0505","article-title":"mRNA-based vaccines and therapeutics for parasitic infections: a comprehensive review","volume":"23","author":"Al-Omari","year":"2025","journal-title":"J. Nanobiotechnol."},{"key":"10.1016\/j.jconrel.2026.115019_bb0510","author":"Intellia Therapeutics"}],"container-title":["Journal of Controlled Release"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0168365926004220?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0168365926004220?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,6,12]],"date-time":"2026-06-12T09:17:43Z","timestamp":1781255863000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0168365926004220"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,7]]},"references-count":102,"alternative-id":["S0168365926004220"],"URL":"https:\/\/doi.org\/10.1016\/j.jconrel.2026.115019","relation":{},"ISSN":["0168-3659"],"issn-type":[{"value":"0168-3659","type":"print"}],"subject":[],"published":{"date-parts":[[2026,7]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"mRNA therapeutics: Molecular mechanisms, delivery platforms, regulatory frameworks, and equitable global access","name":"articletitle","label":"Article Title"},{"value":"Journal of Controlled Release","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.jconrel.2026.115019","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 Elsevier B.V. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}],"article-number":"115019"}}